Gilles Salles

Gilles Salles is a world-leading lymphoma clinician and researcher who has contributed to defining the molecular classification of DLBCL and led pivotal trials including POLARIX, which established polatuzumab vedotin plus R-CHP as superior to R-CHOP in first-line DLBCL. Previously at Hopital Lyon-Sud, his research covers B cell receptor signaling, obinutuzumab optimization, and novel treatment combinations. He is a co-author of major DLBCL treatment guidelines and has published more than 500 papers in hematologic oncology. His leadership of international lymphoma trial networks has shaped modern DLBCL management.